CN109311817A - 取代的含氮芳环化合物及其应用 - Google Patents

取代的含氮芳环化合物及其应用 Download PDF

Info

Publication number
CN109311817A
CN109311817A CN201780031986.0A CN201780031986A CN109311817A CN 109311817 A CN109311817 A CN 109311817A CN 201780031986 A CN201780031986 A CN 201780031986A CN 109311817 A CN109311817 A CN 109311817A
Authority
CN
China
Prior art keywords
compound
deuterium
pharmaceutically acceptable
hydrogen
chloro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201780031986.0A
Other languages
English (en)
Other versions
CN109311817B (zh
Inventor
王义汉
邢青峰
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shenzhen Targetrx Inc
Original Assignee
Shenzhen Targetrx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shenzhen Targetrx Inc filed Critical Shenzhen Targetrx Inc
Publication of CN109311817A publication Critical patent/CN109311817A/zh
Application granted granted Critical
Publication of CN109311817B publication Critical patent/CN109311817B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen

Abstract

本发明涉及了一种取代的含氮芳环化合物及包含该化合物的组合物及其应用。具体地，该发明公开了式（I）所示的含氮芳环化合物，或其晶型、药学上可接受的盐、前药、立体异构体、水合物或溶剂合物的药物组合物。本发明所述化合物可作为血管内皮生长因子受体（VEGFR）抑制剂，进而可适用于制备治疗与蛋白酪氨酸激酶功能失调相关的疾病（如甲状腺癌等）的药物。

Description

PCT国内申请，说明书已公开。

Claims (11)

  1. PCT国内申请，权利要求书已公开。
CN201780031986.0A 2017-02-28 2017-03-07 取代的含氮芳环化合物及其应用 Active CN109311817B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2017/075129 2017-02-28
CN2017075129 2017-02-28
PCT/CN2017/075833 WO2018157411A1 (zh) 2017-02-28 2017-03-07 取代的含氮芳环化合物及其应用

Publications (2)

Publication Number Publication Date
CN109311817A true CN109311817A (zh) 2019-02-05
CN109311817B CN109311817B (zh) 2022-04-22

Family

ID=63369666

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780031986.0A Active CN109311817B (zh) 2017-02-28 2017-03-07 取代的含氮芳环化合物及其应用

Country Status (2)

Country Link
CN (1) CN109311817B (zh)
WO (1) WO2018157411A1 (zh)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110845408A (zh) * 2018-08-20 2020-02-28 润佳（苏州）医药科技有限公司 同位素富集的乐伐替尼
CN112142662A (zh) * 2020-10-27 2020-12-29 南京法恩化学有限公司 一种甲磺酸乐伐替尼的制备方法

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109734661B (zh) * 2018-09-10 2021-12-21 江苏工程职业技术学院 一种乐伐替尼的合成方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1478078A (zh) * 2000-10-20 2004-02-25 ������������ʽ���� 含氮芳环衍生物
EP1604665A1 (en) * 2003-03-10 2005-12-14 Eisai Co., Ltd. C-kit kinase inhibitor
CN1890220A (zh) * 2003-12-25 2007-01-03 卫材株式会社 4－(3－氯－4－(环丙基氨基羰基)氨基苯氧基)－7－甲氧基－6－喹啉羧酰胺的盐或其溶剂合物的结晶及其制备方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1478078A (zh) * 2000-10-20 2004-02-25 ������������ʽ���� 含氮芳环衍生物
EP1604665A1 (en) * 2003-03-10 2005-12-14 Eisai Co., Ltd. C-kit kinase inhibitor
CN1890220A (zh) * 2003-12-25 2007-01-03 卫材株式会社 4－(3－氯－4－(环丙基氨基羰基)氨基苯氧基)－7－甲氧基－6－喹啉羧酰胺的盐或其溶剂合物的结晶及其制备方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
江文峰,等: "氘代作用在药物研究中的应用", 《齐鲁药事》 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110845408A (zh) * 2018-08-20 2020-02-28 润佳（苏州）医药科技有限公司 同位素富集的乐伐替尼
CN112142662A (zh) * 2020-10-27 2020-12-29 南京法恩化学有限公司 一种甲磺酸乐伐替尼的制备方法
CN112142662B (zh) * 2020-10-27 2022-03-08 南京法恩化学有限公司 一种甲磺酸乐伐替尼的制备方法

Also Published As

Publication number Publication date
CN109311817B (zh) 2022-04-22
WO2018157411A1 (zh) 2018-09-07

Similar Documents

Publication Publication Date Title
EP3299369B1 (en) Pyrido-azaheterecydic compound and preparation method and use thereof
CN102532163B (zh) 大环喹唑啉衍生物及其作为mtki的用途
CN102190616B (zh) 一种氘代的ω-二苯基脲的合成及生产的方法和工艺
CN104736155B (zh) 双环化合物作为激酶的抑制剂
CN104530063A (zh) 喹唑啉并杂环类化合物及其制备方法和作为用于治疗癌症的表皮生长因子受体抑制剂的应用
TW200829249A (en) Quinazoline based EGFR inhibitors containing a zinc binding moiety
CN113527335A (zh) 作为egfr抑制剂的大环类化合物及其应用
TW201236684A (en) Pharmaceutically acceptable salts of (E)-N-[4-[[3-chloro-4-(2-pyridylmethoxy)phenyl]amino]-3-cyano-7-ethoxy-6-quinolyl]-3-[(2R)-1-methylpyrrolidin-2-yl]prop-2-enamide, preparation process and pharmaceutical use there of
CN109311817A (zh) 取代的含氮芳环化合物及其应用
RU2300535C2 (ru) Полиморфная форма кристаллического гидрохлорида иринотекана, способ ее получения и фармацевтическая композиция на ее основе
CN104203242A (zh) 取代的喹啉类作为布鲁顿酪氨酸激酶抑制剂
JP2021532181A (ja) Ｓｍａｒｃａ２アンタゴニストとして有用なピリジン−２−オン化合物
Fan et al. Discovery of Dioxino [2, 3-f] quinazoline derivative VEGFR-2 inhibitors exerting significant antipro-liferative activity in HUVECs and mice
EP1696914B1 (en) 3-cyano-quinoline derivatives with antiproliferative activity
JP2020529465A (ja) キナーゼ阻害剤として有用な置換ピラゾロピリミジン
JP2023099159A (ja) 抗腫瘍薬の調製におけるキノリン誘導体と免疫調節剤の組み合わせの使用
CN102452989B (zh) 苯胺取代的喹唑啉衍生物
CN108456214A (zh) 含噁唑或咪唑结构的喹唑啉类化合物及其应用
EP3750894B1 (en) Urea-substituted aromatic ring-linked dioxazoline compound, preparation method therefor, and uses thereof
TWI535724B (zh) 埃克替尼磷酸鹽的新晶型及其用途
CN111533753A (zh) 氨基甲酸酯类氟代喜树碱类化合物及其应用
WO2010083720A1 (zh) 光学纯喹唑啉类化合物
CN110229172A (zh) 一种酰基取代的噁嗪并喹唑啉类化合物、制备方法及其应用
CN103601722B (zh) 新型抗肿瘤化合物
CN100506823C (zh) 作为抗增殖药剂的吡啶并嘧啶和嘧啶并嘧啶衍生物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant